Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Corbus Pharmaceuticals Holdings (CRBP) Net Income towards Common Stockholders (2016 - 2025)

Corbus Pharmaceuticals Holdings has reported Net Income towards Common Stockholders over the past 9 years, most recently at -$11.0 million for Q4 2023.

  • For Q4 2023, Net Income towards Common Stockholders fell 2.2% year-over-year to -$11.0 million; the TTM value through Dec 2023 reached -$48.0 million, down 20.47%, while the annual FY2024 figure was $4.4 million, 109.07% up from the prior year.
  • Net Income towards Common Stockholders for Q4 2023 was -$11.0 million at Corbus Pharmaceuticals Holdings, down from -$10.5 million in the prior quarter.
  • Over five years, Net Income towards Common Stockholders peaked at $2.2 million in Q2 2019 and troughed at -$38.1 million in Q2 2020.
  • A 5-year average of -$17.1 million and a median of -$14.6 million in 2021 define the central range for Net Income towards Common Stockholders.
  • Biggest five-year swings in Net Income towards Common Stockholders: surged 117.76% in 2019 and later crashed 1870.07% in 2020.
  • Year by year, Net Income towards Common Stockholders stood at -$27.0 million in 2019, then rose by 23.03% to -$20.8 million in 2020, then soared by 51.96% to -$10.0 million in 2021, then fell by 7.99% to -$10.8 million in 2022, then dropped by 2.2% to -$11.0 million in 2023.
  • Business Quant data shows Net Income towards Common Stockholders for CRBP at -$11.0 million in Q4 2023, -$10.5 million in Q3 2023, and -$9.2 million in Q2 2023.